| CSE | % | CRE | % | P-value |
---|---|---|---|---|---|
NÂ =Â 38,910 | NÂ =Â 1227 | ||||
Infection characteristics | |||||
 Sepsis | 12,726 | 32.7% | 409 | 33.3% | 0.039 |
 Pneumonia | 5060 | 13.0% | 187 | 15.2% | |
 UTI | 21,124 | 54.3% | 631 | 51.4% | |
 HCA | 13,782 | 35.4% | 718 | 58.5% | <0.001 |
Illness severity measures by day 2 | |||||
 ICU admission | 15,876 | 40.8% | 687 | 56.0% | <0.001 |
 Mechanical ventilation | 6092 | 15.7% | 437 | 35.6% | <0.001 |
 Vasopressors | 5798 | 14.9% | 205 | 16.7% | 0.081 |
Antibiotics administered by day 2 | |||||
 Aminoglycosides | 3843 | 9.9% | 242 | 19.7% | <0.001 |
 Antipseudomonal penicillins | 6403 | 16.5% | 313 | 25.5% | <0.001 |
 Antipseudomonal floroquinolones | 18,468 | 47.5% | 406 | 33.1% | <0.001 |
 Antipseudomonal penicillins with beta-lactamase inhibitors | 19,727 | 50.7% | 617 | 50.3% | 0.775 |
 Extended spectrum cephalosporins | 13,327 | 34.3% | 415 | 33.8% | 0.755 |
 Folate pathway inhibitors | 251 | 0.6% | 12 | 1.0% | 0.155 |
 Penicillins with beta-lactamase inhibitors | 854 | 2.2% | 26 | 2.1% | 0.837 |
 Polymyxins | 126 | 0.3% | 24 | 2.0% | <0.001 |
 Tetracyclines | 248 | 0.6% | 6 | 0.5% | 0.519 |
 Tigecycline | 586 | 1.5% | 86 | 7.0% | <0.001 |
 Aztreonam | 1740 | 4.5% | 56 | 4.6% | 0.878 |
Empiric treatment appropriateness | |||||
 Non-IET | 32,197 | 82.7% | 513 | 41.8% | <0.001 |
 IET | 4336 | 11.1% | 648 | 52.8% | |
 Indeterminate | 2337 | 6.0% | 66 | 5.4% | |
Hospital outcomes | |||||
 Mortality | 3958 | 10.2% | 178 | 14.5% | <0.001 |
 Mean (SD) LOS, days | 9.6 (10.7) |  | 15.6 (17.4) |  | <0.001 |
 Median [IQR] LOS, days | 7 [4, 11] |  | 10 [6, 18] |  | <0.001 |
 Mean (SD) costs, $ | 20,601 (29702) |  | 38,494 (46,964) |  | <0.001 |
 Median [IQR] costs, $ | 13,020 [7501, 24,237] |  | 22,909 [12,988, 42,815] |  | <0.001 |
Hospital outcomes stratified by infection type | |||||
 UTI | |||||
  Mortality | 1873 | 8.9% | 78 | 12.4% | 0.002 |
  Mean (SD) LOS, days | 9.0 (9.4) |  | 14.6 (15.9) |  | <0.001 |
  Median [IQR] LOS, days | 7 [4, 11] |  | 10 [6, 17] |  | <0.001 |
  Mean (SD) costs, $ | 19,036 (24,494) |  | 33,400 (37,662) |  | <0.001 |
  Median [IQR] costs, $ | 12,082 [7104, 21,822] |  | 21,154 [12,687, 39,374] |  | <0.001 |
 Sepsis | |||||
  Mortality | 1660 | 13.0% | 81 | 19.8% | <0.001 |
  Mean (SD) LOS, days | 10.9 (12.6) |  | 18.0 (20.8) |  | <0.001 |
  Median [IQR] LOS, days | 7 [4, 13] |  | 11 [7, 21] |  | <0.001 |
  Mean (SD) costs, $ | 26,793 (37,390) |  | 50,038 (60,602) |  | <0.001 |
  Median [IQR] costs, $ | 15,614 [8584, 30,317] |  | 27,264 [14,581, 57,825] |  | <0.001 |
 Pneumonia | |||||
  Mortality | 425 | 8.4% | 19 | 10.2% | 0.395 |
  Mean (SD) LOS, days | 9.2 (10.4) |  | 13.4 (13.0) |  | <0.001 |
  Median [IQR] LOS, days | 7 [4, 10] |  | 9 [6, 16] |  | <0.001 |
  Mean (SD) costs, $ | 19,250 (25,743) |  | 30,432 (35,089) |  | <0.001 |
  Median [IQR] costs, $ | 11,826 [7076, 21,100] |  | 19,820 [12,220, 35,713] |  | <0.001 |